Multiple outlets report that prescriptions for a specific ivermectin-based cancer “alternative” regimen increase after Mel Gibson publicly promoted it during a Joe Rogan podcast appearance. A review of U.S. national prescription data finds that prescribing for a combination treatment that pairs ivermectin with a benzimidazole doubled following the celebrity endorsement, according to the studies cited by the outlets.
The coverage centers on how demand changes align with the timing of Gibson’s podcast comments, in which he described the regimen as a potential cure for advanced cancer for people he knew. Fox News and The New York Times highlight that the spike is seen among patients with cancer, while Gizmodo and MedPage Today describe the rise in prescriptions for the two-drug combination after the interview.
The reports characterize the regimen as controversial and framed as a possible cancer treatment outside mainstream clinical guidance. Across sources, the central points are the increase in prescriptions, the specific drug combination involved, and the temporal association with the podcast promotion.
